Sec Form 4 Filing - ARCH Venture Fund VIII, L.P. @ Codiak BioSciences, Inc. - 2020-10-16

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person ARCH Venture Fund VIII, L.P. 2. Issuer Name and Ticker or Trading Symbol Codiak BioSciences, Inc. [ CDAK] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 8755 WEST HIGGINS ROAD, SUITE 1025 3. Date of Earliest Transaction (MM/DD/YY) 10/16/2020 (Street) CHICAGO, IL60631 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 10/16/2020 C 1,784,572 A 1,848,535 I See Footnote ( 2 ) Common Stock 10/16/2020 C 831,521 A 831,521 I See Footnote ( 3 ) Common Stock 10/16/2020 C 420,368 A 2,268,903 I See Footnote ( 2 ) Common Stock 10/16/2020 C 326,953 A 1,158,474 I See Footnote ( 3 ) Common Stock 10/16/2020 C 191,721 A 1,350,195 I See Footnote ( 3 ) Common Stock 10/16/2020 P 235,000 A $ 15 2,503,903 I See Footnote ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A Preferred Stock ( 1 ) 10/16/2020 C 13,950,000 ( 1 ) ( 1 ) Common Stock 1,784,572 ( 1 ) 0 I See Footnote ( 2 ) Series A Preferred Stock ( 1 ) 10/16/2020 C 6,500,000 ( 1 ) ( 1 ) Common Stock 831,521 ( 1 ) 0 I See Footnote ( 3 ) Series B Preferred Stock ( 4 ) 10/16/2020 C 3,000,000 ( 4 ) ( 4 ) Common Stock 420,368 ( 4 ) 0 I See Footnote ( 2 ) Series B Preferred Stock ( 4 ) 10/16/2020 C 2,333,333 ( 4 ) ( 4 ) Common Stock 326,953 ( 4 ) 0 I See Footnote ( 3 ) Series C Preferred Stock ( 5 ) 10/16/2020 C 1,320,097 ( 5 ) ( 5 ) Common Stock 191,721 ( 5 ) 0 I See Footnote ( 3 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other ARCH Venture Fund VIII, L.P. 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL60631 X ARCH Venture Fund VIII Overage, L.P. 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL60631 X CRANDELL KEITH 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL60631 X BYBEE CLINTON 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL60631 X NELSEN ROBERT 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL60631 X ARCH Venture Partners VIII, LLC 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL60631 X ARCH Venture Partners VIII, L.P. 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO, IL60631 X Signatures ARCH Venture Fund VIII, L.P. By: ARCH Venture Partners VIII, L.P., its General Partner By: ARCH Venture Partners VIII, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director 10/20/2020 Signature of Reporting Person Date ARCH Venture Fund VIII Overage, L.P. ARCH Venture Partners VIII, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director 10/20/2020 Signature of Reporting Person Date Keith Crandell, Managing Director By: /s/ Mark McDonnell, as Attorney-in-Fact 10/20/2020 Signature of Reporti ng Person Date Clinton Bybee, Managing Director By: /s/ Mark McDonnell, as Attorney-in-Fact 10/20/2020 Signature of Reporting Person Date Robert Nelsen, Managing Director By: /s/ Mark McDonnell, as Attorney-in-Fact 10/20/2020 Signature of Reporting Person Date ARCH Venture Partners VIII, LLC By: /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director 10/20/2020 Signature of Reporting Person Date ARCH Venture Partners VIII, L.P. By: ARCH Venture Partners VIII, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director 10/20/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Each share of Series A Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-7.8170 basis upon the closing of the Issuer's initial public offering on October 16, 2020 and had no expiration date. ( 2 )Shares held by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII"). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"), which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to beneficially own the shares held by ARCH Fund VIII. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. ( 3 )Shares held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage"). The sole general partner of ARCH Fund Overage is ARCH VIII LLC, which may be deemed to beneficially own the shares held by ARCH Fund Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. ( 4 )Each share of Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-7.1366 basis upon the closing of the Issuer's initial public offering on October 16, 2020 and had no expiration date. The reporting person previously reported shares of common stock into which the Series B Preferred Stock was convertible based on a 1-for-7.1295 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. ( 5 )Each share of Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-6.8855 basis upon the closing of the Issuer's initial public offering on October 16, 2020 and had no expiration date. The reporting person previously reported shares of common stock into which the Series C Preferred Stock was convertible based on a 1-for-6.8758 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.